Mittwoch, 5. November 2008

Efalizumab (Raptiva) und progressive multifokale Leukenzephalopathie

Die Arzneimittelkommission der Deutschen Ärzte teilt mit: Der Hersteller von Raptiva® (Efalizumab) informiert in einer Mitteilung über den Fall einer progressiven multifokalen Leukenzephalopathie (PML) bei einem Patienten, der Raptiva® etwa vier Jahre lang als Monotherapie erhalten hat.

1 Kommentar:

Anonym hat gesagt…

I have read carefully the blog posts, and I believe that I can assist you in locating more information relating to the topic. Although there are many cures to skin disease and head Psoriasis, there is only one proven and very efficient remedy to reduce the disease to a negligible state for long periods of time and, hence, to reduce the overall suffering caused by it.
In a study published by the Dead Sea in Israel, it seems that the perception of visitors in the medical-tourism sector has been correct. At least, according to the study, it is now official. The Dead Sea has healing attributes that cause the disease to regress. It is possible to sign up to the study at the following address:
Thank you again for the good work that you are doing – on behalf of all that are suffering.